Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Connect with us

Hi, what are you looking for?

slide 3 of 2
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Business

Business

Novo Nordisk negotiating Biocorp control.

The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a ... The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres, north-central France, April 21, 2016. REUTERS/Guillaume Souvant/Pool
The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a ... The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres, north-central France, April 21, 2016. REUTERS/Guillaume Souvant/Pool

Listen to the article now

On Monday, Novo Nordisk announced plans to acquire a majority share in French medical device maker Biocorp (ALCOR.PA).

The Danish business said it was in exclusive negotiations with Bio Jag, Biocorp’s largest shareholder, to buy its approximately 45% position in the French company for 35.0 euros ($37.44) per share in cash.

The firms said Biocorp’s transaction value is around 154 million euros, a 19.5% premium over its June 2 closing market price.

Biocorp’s 19.0% minority owners will transfer shares to Novo Nordisk in a squeeze-out.

Novo said the block purchase should happen in the third quarter of 2023 and the subsequent offer in September.


Comment Template

You May Also Like

Business

In response to recent US tariffs on Canadian goods, Ontario imposed a 25% levy on electricity exports to New York, Michigan, and Minnesota. This...

Business

Major US market indices fell significantly, with the S&P 500 reaching a six-month low. This slump coincides with growing concerns about a probable US...

Business

Hims & Hers Health reported strong Q4 2024 revenue growth, surpassing expectations, but its stock fell 18% due to margin concerns and regulatory scrutiny...

Business

The Saver’s Credit helps low- and moderate-income earners reduce their tax bill while saving for retirement. Many eligible taxpayers miss out due to low...

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok